Karyopharm Therapeutics Inc (KPTI)

11.70
0.39 3.40
NASDAQ : Health Care
Prev Close 11.31
Open 11.33
Day Low/High 11.25 / 11.66
52 Wk Low/High 4.83 / 23.59
Volume 29.61K
Avg Volume 258.40K
Exchange NASDAQ
Shares Outstanding 41.90M
Market Cap 453.79M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017

Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017

Conference Call Scheduled for Thursday, March 16, 2017 at 8:30 a.m. ET

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options

Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options

Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $10.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $7.50 strike, which has a bid at the time of this writing of 85 cents.

Short Interest Jumps 19.7% For KPTI

Short Interest Jumps 19.7% For KPTI

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 289,025 share increase in total short interest for Karyopharm Therapeutics Inc , to 1,756,850, an increase of 19.69% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Karyopharm And The Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders

Karyopharm And The Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders

- Webcast Event Scheduled for Monday, December 5, 2016 at 8:15 PM PT -

Karyopharm To Ring The Nasdaq Stock Market Closing Bell

Karyopharm To Ring The Nasdaq Stock Market Closing Bell

Celebration Commemorating the Company's 8th Anniversary

Karyopharm To Report Third Quarter 2016 Financial Results On November 7, 2016

Karyopharm To Report Third Quarter 2016 Financial Results On November 7, 2016

Conference Call Scheduled for Monday, November 7, 2016 at 5:00 p.m. ET

Karyopharm Therapeutics is Now Oversold (KPTI)

Karyopharm Therapeutics is Now Oversold (KPTI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 32.4% Annualized Using Options

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 32.4% Annualized Using Options

Investors considering a purchase of Karyopharm Therapeutics Inc shares, but tentative about paying the going market price of $8.56/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $7.50 strike, which has a bid at the time of this writing of 80 cents.

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.